
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Hum. Dyn.
Sec. Environment, Politics and Society
Volume 7 - 2025 | doi: 10.3389/fhumd.2025.1543183
This article is part of the Research Topic Asian Medical Industries: Beyond Tradition, Beyond Medicine, Beyond Asia View all articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Attempts to facilitate Sowa Rigpa practice in European countries are fairly recent and mostly happen under precarious circumstances, especially since the restrictive legal environment severely limits access to Sowa Rigpa medicinal preparations. Another issue is the incompatibility of common Sowa Rigpa pharmaceutical preparations in the form of powders and pills with modern lifestyles and tastes that, simple as it may seem, presents a major practical challenge for Tibetan medicine in the west. To remedy these limitations and incompatibilities, some more innovative ways of medicine production emerge that are supposed to increase accessibility. Looking at small-scale transnational collaborations between practitioners, laboratories, and companies as complex multi-sited entanglements, this paper follows the emergence of Daknang Herbal Products as a low-key industrial aspiration between Latvia and Nepal that attempts to realize calls for innovation and seeks to explore novel paths of engaging Sowa Rigpa medicinal preparations as food supplements in European contexts. By examining Daknang's path towards the establishment of Sowa Rigpa pharmaceuticals as self-medicated reformulated extracts produced in Europe, this paper addresses the questions to what extent Sowa Rigpa medicines need to be transformed to enter western food supplement markets, and what kind of concerns and moral discourses about 'negative aspirations' surround the innovation of established forms of medicinal preparations. The aim is to show that looking at transnational business collaborations offers interesting perspectives for the Asian medicine industry that tend to be overlooked due to their small-scale nature, but which are nevertheless involved in the innovation of Asian medicines for global markets.
Keywords: Sowa Rigpa (Tibetan medicine), Dietary Supplements, innovation, Herbal extracts, reformulation
Received: 11 Dec 2024; Accepted: 02 Apr 2025.
Copyright: © 2025 Mundelius and Sprisevska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Patricia Mundelius, University of Edinburgh, Edinburgh, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.